Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 13/20 | 0.47 |
| ▸ | KCNJ11 | Q14654 | 13/20 | 0.47 |
| ▸ | BRD4 | O60885 | 6/20 | 0.38 |
| ▸ | BRDT | Q58F21 | 6/20 | 0.38 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.32 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6856477 | 0.88 | ABCC9 (0.42) | ABCC9KCNJ11BRD4BRDTABCC8 | |
| SCHEMBL6646732 | 0.87 | HPGD (0.36) | ABCC9KCNJ11BRD4BRDTABCC8 | |
| SCHEMBL6643748 | 0.84 | ABCC9 (0.55) | ABCC9KCNJ11BRD4BRDTABCC8 | |
| SCHEMBL6854166 | 0.84 | ABCC9 (0.45) | ABCC9KCNJ11BRD4BRDTABCC8 | |
| SCHEMBL6642942 | 0.84 | BRD4 (0.50) | ABCC9KCNJ11BRD4BRDTTSHR | |
| SCHEMBL6644971 | 0.83 | ABCC9 (0.71) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL6643969 | 0.83 | ABCC9 (0.54) | ABCC9KCNJ11BRD4BRDTABCC8 | |
| SCHEMBL6646407 | 0.83 | ABCC9 (0.45) | ABCC9KCNJ11BRD4BRDTABCC8 | |
| SCHEMBL6642305 | 0.83 | ABCC9 (0.39) | ABCC9KCNJ11BRD4BRDTABCC8 | |
| SCHEMBL6647129 | 0.83 | ABCC9 (0.44) | ABCC9KCNJ11BRD4BRDTABCC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6780872-B2 | ASTHMA; ANTIEPILEPTIC AGENTS; SEXUAL DISORDERS | ABBOTT LABORATORIES | 2004-08-24 | — | — | US | disclosed |
| US-20030171394-A1 | Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers | DRIZIN IRENE (US) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171394-A1 | Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers | KCNJ2, KCNH1, KCNJ1 | ABCC9 741/4885KCNJ11 4/4885BRD4 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.